Stifel cuts MaxCyte stock price target to $9 from $11

Published 12/03/2025, 15:08
Stifel cuts MaxCyte stock price target to $9 from $11

On Wednesday, Stifel analysts adjusted their outlook on MaxCyte Inc. (NASDAQ:MXCT), reducing the price target from $11.00 to $9.00, while still maintaining a Buy rating on the company’s shares. According to InvestingPro data, the stock currently trades at $3.03, near its 52-week low of $3.17, suggesting significant upside potential to analysts’ target range of $6-$9. The revision follows MaxCyte’s pre-announcement of its fourth-quarter results around the time of the J.P. Morgan Healthcare Conference, which did not come as a surprise to the market. Management provided guidance for the year 2025, forecasting core revenue growth of 8-15%, inclusive of contributions from the SeQure Dx acquisition and an additional $5 million in SPL revenues.

The company’s projected revenues fall short of Wall Street expectations, leading analysts to anticipate a decline in MaxCyte’s stock price in the morning trading session. Despite recent headwinds, InvestingPro analysis shows the company maintains strong financial health with a current ratio of 9.81 and more cash than debt on its balance sheet. InvestingPro subscribers have access to 7 additional key insights about MXCT’s financial position. Despite the lower guidance, Stifel analysts see potential for the company to outperform its own forecasts, especially if the end markets show improvement, which is not currently factored into the company’s projections.

The analysts at Stifel believe that the drug development environment has the potential to strengthen throughout 2025. However, they also note that investors may be cautious and prefer to witness tangible signs of market recovery before gaining confidence in the stock. Stifel continues to favor MaxCyte as an investment opportunity, given its involvement in what is expected to be a recovery year for cell therapy. Nevertheless, they caution that the realization of this thesis may progress at a slower pace than initially anticipated. The company has demonstrated solid historical performance with revenue growth of 19.85% over the last twelve months, though InvestingPro data indicates analysts don’t expect profitability this year.

In other recent news, MaxCyte Inc. reported a 6% year-over-year decline in total revenue for 2024, despite a 9% increase in core revenue. The decline was influenced by a significant drop in milestone-based revenue, which faced tough comparisons to the previous year’s payments from Vertex (NASDAQ:VRTX). MaxCyte ended the year with 28 active strategic platform license agreements, anticipating future economic benefits. Looking ahead, the company has projected an 8-15% growth in core revenue for 2025, including contributions from its recent acquisition of SeQure Dx. BTIG analyst Mark Massaro adjusted the price target for MaxCyte to $6.00 from $8.00, maintaining a Buy rating, citing macroeconomic challenges in the biopharmaceutical sector. Meanwhile, MaxSight reported a 45% decline in Q4 2024 revenue, although it exceeded earnings per share expectations. MaxSight projects an 8-15% growth in core revenue for 2025, with the acquisition of SecurDx expected to contribute significantly.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.